# US 2005/0097626 A1 · Tumor suppressor gene, p28ing5

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0097626 A1
- Document ID: US20050097626A1
- Status: Published application
- Kind: A1
- Application number: 10/502,431
- Filed: 2003-01-23
- Published: 2005-05-05
- Earliest claimed: 2002-01-23
- Assignees: The United States of America as represented by the Department of Health and Human Services
- Inventors: Curtis Harris; Remy Pedeux; Makoto Nagashima; Masayuki Shiseki
- Web page: https://patentgrep.com/patent/US20050097626A1

## CPC

- C12N 5/0693: {Tumour cells; Cancer cells}
- A61P 35/00: Antineoplastic agents
- C07K 14/4703: {Inhibitors; Suppressors}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.

## Claims

### Claim 1

A purified p28ING5 tumor suppressor protein having a sequence comprising amino acid residues 1-13 and 241-356 of SEQ ID NO: 2, or a sequence having one or more conservative substitutions thereof.

### Claim 2 (depends on 1)

The tumor suppressor protein of claim 1, wherein the tumor suppressor protein comprises the sequence of SEQ ID NO: 2.

### Claim 3 (depends on 1)

A recombinant polynucleotide encoding the protein of claim 1.

### Claim 4 (depends on 3)

The recombinant polynucleotide of claim 3, wherein the recombinant polynucleotide has a sequence comprising of SEQ ID NO: 1.

### Claim 5 (depends on 3)

A recombinant nucleic acid molecule comprising a promoter sequence operably linked to the recombinant polynucleotide of claim 3.

### Claim 6 (depends on 5)

The recombinant nucleic acid molecule of claim 5, wherein the recombinant polynucleotide is in antisense orientation relative to the promoter sequence.

### Claim 7 (depends on 5)

A recombinant vector comprising the recombinant nucleic acid molecule of claim 5.

### Claim 8 (depends on 5)

A cell transfected with the recombinant nucleic acid molecule of claim 5.

### Claim 9 (depends on 7)

A cell transfected with the recombinant vector of claim 7.

### Claim 10 (depends on 8)

A transgenic non-human animal, comprising the cell of claim 8.

### Claim 11 (depends on 3)

The recombinant polynucleotide of claim 3, wherein the recombinant polynucleotide is at least 10 nucleotides in length and specifically hybridizes under low stringency conditions to nucleotide residues 1-39 or 723-1068 of SEQ ID NO: 1.

### Claim 12 (depends on 11)

The oligonucleotide according to claim 11, wherein the oligonucleotide comprises at least 10 contiguous nucleotides of the nucleotides 1-39 of the sequence set forth as SEQ ID NO: 1, or a variant thereof, that hybridizes to SEQ ID NO: 1 under high stringency conditions.

### Claim 13 (depends on 11)

The oligonucleotide according to claim 11, wherein the oligonucleotide comprises at least 10 contiguous nucleotides of the nucleotides 723-1068 of the sequence set forth as SEQ ID NO: 1, or a variant thereof, that hybridizes to SEQ ID NO: 1 under high stringency conditions.

### Claim 14 (depends on 11)

The isolated oligonucleotide according to claim 11, wherein the oligonucleotide comprises at least 20 contiguous nucleotides of the nucleotides 1-39 of the sequence set forth as SEQ ID NO: 1, or a variant thereof, that hybridizes to SEQ ID NO: 1 under high stringency conditions.

### Claim 15 (depends on 11)

The isolated oligonucleotide according to claim 11, wherein the oligonucleotide comprises at least 20 contiguous nucleotides of the nucleotides 723-1068 of the sequence set forth as SEQ ID NO: 1, or a variant thereof, that hybridizes to SEQ ID NO: 1 under high stringency conditions.

### Claim 16 (depends on 11)

The oligonucleotide according to claim 11, wherein the oligonucleotide hybridizes with a nucleic acid sequence comprising nucleotides 1-39 of the sequence as set forth in SEQ ID NO: 1 under wash conditions of 65° C., 0.5×SSC and 0.1% SDS.

### Claim 17 (depends on 11)

The oligonucleotide according to claim 11, wherein the oligonucleotide hybridizes with a nucleic acid sequence comprising nucleotides 1-39 of the sequence as set forth in SEQ ID NO: 1 under wash conditions of 55° C., 2.0×SSC and 0.1% SDS.

### Claim 18 (depends on 11)

The oligonucleotide according to claim 11, wherein the oligonucleotide hybridizes with a nucleic acid sequence comprising nucleotides 723-1068 of the sequence as set forth in SEQ ID NO: 1 under wash conditions of 65° C., 0.5×SSC and 0.1% SDS.

### Claim 19 (depends on 11)

The oligonucleotide according to claim 11, wherein the oligonucleotide hybridizes with a nucleic acid sequence comprising nucleotides 723-1068 of the sequence as set forth in SEQ ID NO: 1 under wash conditions of 55° C., 2.0×SSC and 0.1% SDS.

### Claim 20 (depends on 4)

A method of inhibiting cellular proliferation, comprising:
transfecting a cell with an expression vector comprising a promoter operably linked to nucleotides 1-39 and 723-1068 of the recombinant polynucleotide of claim 4, thereby inhibiting cellular proliferation.

### Claim 21 (depends on 20)

The method of claim 20, wherein the expression vector comprises a promoter operably linked to a nucleic acid sequence as set forth in SEQ ID NO: 1, or a conservative substitution thereof.

### Claim 22 (depends on 1)

A method of inhibiting cellular proliferation, comprising: contacting a cell with the protein of claim 1, thereby inhibiting cellular proliferation.

### Claim 23 (depends on 22)

The method of claim 22, wherein the protein has an amino acid sequence comprising the sequence set forth in SEQ ID NO: 2, or a conservative substitution thereof.

### Claim 24 (depends on 6)

A method for enhancing cellular proliferation, comprising transfecting a cell with an expression vector comprising the recombinant nucleic acid molecule of claim 6.

### Claim 25 (depends on 24)

The method of claim 24, wherein the expression vector comprises a nucleotide sequence as set forth in SEQ ID NO: 1, or a conservative substitution thereof, operably linked to a promoter sequence.

### Claim 26 (depends on 2)

A specific binding agent that specifically binds an epitope of the protein encoded by the protein of claim 2.

### Claim 28 (depends on 4)

A method of screening for an agent that modulates p28ING5 tumor suppressor activity, the method comprising:
transfecting a cell with an expression vector, wherein the expression vector comprises the recombinant polynucleotide of claim 4, or a conservative substitution thereof, operably linked to a promoter sequence;
contacting the cell with a test agent; and
detecting a change in the level of expression of the p28ING5 protein, wherein a change in the level is indicative that the test agent is an agent that modulates the expression of the p28ING5 tumor suppressor protein.

### Claim 29 (depends on 4)

A method of detecting a p28ING5 tumor suppressor protein in a biological sample, comprising:
amplifying the recombinant polynucleotide of claim 4, or a conservative substitution thereof, with two or more oligonucleotide primers that specifically bind the recombinant polynucleotide;
detecting a level of an amplified product, thereby detecting the p28ING5 tumor suppressor protein.

### Claim 30 (depends on 4)

A method of diagnosing the presence of a tumor in a subject, comprising:
amplifying the recombinant polynucleotide of claim 4, or a conservative substitution thereof, in a sample using two or more oligonucleotide primers that specifically bind the recombinant polynucleotide;
detecting an amplified product if one is produced, wherein absence of the amplified product is indicative of the presence of a tumor in a subject.

### Claim 31 (depends on 30)

The method of claim 30, wherein the tumor comprises a breast tumor, a lung tumor, a colon tumor, a pancreatic tumor, a liver tumor, a brain tumor, a skin tumor, a prostate tumor, a testicular tumor, an ovarian tumor, a stomach tumor, or a tumor of the blood.

### Claim 32 (depends on 30)

The method of claim 30, wherein the subject is a human.

### Claim 33 (depends on 30)

The method of claim 30, wherein the sample comprises blood, a blood product, urine, saliva, a tissue biopsy, a surgical specimen, an amniocentesis sample, or autopsy material.

### Claim 34 (depends on 30)

The method of claim 30, further comprising reverse transcribing a mRNA having a sequence as shown in SEQ ID NO: 1, or a conservative substitution thereof, in the sample.

### Claim 35 (depends on 30)

The method of claim 30, further comprising identifying a change in the level of the amplified product compared to a second sample, or identifying a mutation in the amplified product.

### Claim 36 (depends on 35)

The method of claim 35, wherein identifying a change in the level of amplified product comprises Southern blot analysis, quantitative polymerase chain reaction or semi-quantitative polymerase chain reaction.

### Claim 37 (depends on 35)

The method of claim 35, wherein identifying a mutation in the amplified product comprises sequencing, chemical cleavage, denaturing gradient gel electrophoresis, or hybridization with allele specific oligonucleotides.

### Claim 38 (depends on 2)

A method of treating a neoplasm, comprising contacting a neoplastic cell with the protein of claim 2, or a conservative substitution thereof.

### Claim 39

An in vitro assay kit for determining whether or not a subject has a biological condition associated with p28ING5 expression by detecting an underabundance of p28ING5 protein in a sample of tissue and/or body fluids from the subject, comprising:
a container comprising an antibody specific for p28ING5 protein; and
instructions for using the kit, the instructions indicating steps for performing a method to detect the presence of p28ING5 protein in the sample; and
analyzing data generated by the method, wherein the instructions indicate that underabundance of p28ING5 protein in the sample indicates that the individual has the biological condition.

### Claim 40

An in vitro amplification assay kit for determining whether or not a subject has a biological condition associated with a p28ING5 nucleic acid by detecting presence and/or quantity of a nucleic acid that encodes p28ING5 protein in a sample of tissue and/or body fluids from the subject, the kit comprising:
a first container comprising an in vitro amplification primer that specifically amplifies the nucleic acid that encodes p28ING5 protein;
a second container comprising a size marker, the size marker being the expected size of amplified DNA if the nucleic acid that encodes p28ING5 protein is present in the sample; and
instructions for using the kit, wherein the instructions indicate steps for performing a method to detect and/or quantify the nucleic acid that encodes p28ING5 protein in the sample; and analyzing data generated by the method, wherein the instructions indicate that the presence of increased nucleic acid that encodes p28ING5 protein in the sample indicates that the subject has the biological condition.

### Claim 41 (depends on 3)

The recombinant polynucleotide of claim 3, wherein the recombinant polynucleotide has a sequence comprising nucleotide residues 1-39 of SEQ ID NO: 1.

### Claim 42 (depends on 3)

The recombinant polynucleotide of claim 3, wherein the recombinant polynucleotide has a sequence comprising nucleotide residues 723-1068 of SEQ ID NO: 1.

### Claim 43 (depends on 3)

The recombinant polynucleotide of claim 3, wherein the recombinant polynucleotide has a sequence comprising nucleotide residues 1-39 and 723-1068 of SEQ ID NO: 1.
